Associate Director, Opinion Leader Engagement

Remote

Auto‑apply with AI Apply

Not SpecifiedCompensation

Junior (1 to 2 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Pharmaceuticals, HealthcareIndustries

Requirements

The ideal candidate should possess a Bachelor’s degree and demonstrate a strong understanding of the pharmaceutical industry, with experience in KOL engagement and medical affairs preferred. Excellent communication, interpersonal, and relationship-building skills are essential, along with the ability to work independently and collaboratively within a team environment.

Responsibilities

This role involves identifying, developing, and maintaining strong relationships with KOLs, facilitating engagements between KOLs and Cytokinetics, gathering insights on data and publications, supporting Commercial Advisory Boards, contributing to speaker bureau planning, monitoring speaker utilization, and coordinating KOL participation during commercial events. The OLE will also provide compliant insights reports and session summaries, and lead or support strategic internal projects aligned with commercial objectives.

Skills

Relationship-building

Engagement facilitation

KOL insights gathering

CRM proficiency

Stakeholder collaboration

Strategic thinking

Project management

Event management

Cytokinetics

Develops drugs for muscle function disorders

About Cytokinetics

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a pipeline of drugs, including omecamtiv mecarbil and reldesemtiv, which are in various stages of clinical trials. Unlike many competitors, Cytokinetics emphasizes rigorous scientific research and has conducted over 50 clinical trials to ensure the effectiveness of its treatments. The goal is to bring new therapies to market that address the unmet needs of patients suffering from conditions like heart failure, ALS, and HCM.

South San Francisco, CaliforniaHeadquarters

1998Year Founded

$58.4MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

501-1,000Employees

Risks

Increased competition could impact market share and profitability.

Potential delays in clinical trials could hinder drug commercialization.

Dependence on strategic partnerships may expose Cytokinetics to risks if challenges arise.

Differentiation

Cytokinetics focuses on muscle activators and inhibitors for cardiovascular and neuromuscular diseases.

The company has a robust pipeline including omecamtiv mecarbil and aficamten.

Cytokinetics engages in strategic partnerships, like with Sanofi, to expand market reach.

Upsides

Recent investments indicate strong interest in muscle activators and inhibitors.

Strategic partnerships, like with Sanofi, expand market reach and potential revenue.

Significant funding from Royalty Pharma supports commercial launch and R&D advancements.

Land your dream remote job 3x faster with AI

Try Jobo Free